Ashley County, Ark. v. Pfizer, Inc.

552 F.3d 659, 2009 U.S. App. LEXIS 19, 2009 WL 17992
CourtCourt of Appeals for the Eighth Circuit
DecidedJanuary 5, 2009
Docket08-1491
StatusPublished
Cited by450 cases

This text of 552 F.3d 659 (Ashley County, Ark. v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ashley County, Ark. v. Pfizer, Inc., 552 F.3d 659, 2009 U.S. App. LEXIS 19, 2009 WL 17992 (8th Cir. 2009).

Opinion

HANSEN, Circuit Judge.

Twenty individual counties in Arkansas brought this civil suit against Pfizer, Inc., PDK Labs, Inc., Warner Lambert Company, LLC, Johnson & Johnson, Perrigo Company, and various John Does (collectively “Defendants”), 1 each of whom manu *663 factures or distributes products containing ephedrine or pseudoephedrine. The complaint sought compensation to recoup the costs expended by the counties in dealing with the societal effects of the methamphetamine epidemic in Arkansas, with liability premised on the use of the Defendants’ products in the methamphetamine manufacturing process. Sixteen of the counties (collectively “Counties”) appeal the district court’s 2 order granting the Defendants’ motion for judgment on the pleadings under Rule 12(c) of the Federal Rules of Civil Procedure, and we affirm.

I.

Because we are reviewing a judgment granted on the pleadings, we view all the facts pleaded by the Counties, the nonmovants, as true, and we make all reasonable inferences in the Counties’ favor. Poehl v. Countrywide Home Loans, Inc., 528 F.3d 1093, 1096 (8th Cir.2008). Methamphetamine is a highly addictive, synthetic drug that, according to the Counties, cannot be manufactured, or “cooked,” without either ephedrine or pseudoephed-rine. In Arkansas, methamphetamine is manufactured primarily in small toxic labs (“STLs”) located in homes, tents, barns, or hotel rooms. According to the Counties, Arkansas has one of the highest numbers of STLs in the nation. The manufacturing process is dangerous, often resulting in explosions, chemical burns, chemical spills, and toxic fumes. The Counties allege that they have spent significant amounts of taxpayer dollars combating the manufacture of methamphetamine, including law enforcement costs to locate, eliminate, and clean up STLs where the methamphetamine is manufactured; prison and jail costs to house illegal users, dealers, and manufacturers; addiction treatment costs for users and addicts; costs to family service agencies for housing and treating children whose parents are arrested for methamphetamine-related charges; and costs for treating the physical side effects of methamphetamine use and exposure to its production.

The Defendants are manufacturers and distributors of over-the-counter cold and allergy medications containing either ephedrine or pseudoephedrine. None of the Defendants are retailers, nor do they sell the medications directly to the public. The Counties allege that the Defendants marketed and sold their products in Arkansas knowing that the products were being used illegally to manufacture methamphetamine. 3 The Counties allege that the Defendants knew that their products were being used illegally at least as early as 1986 when the federal Drug Enforcement Administration (DEA) began pushing for controls over the sale of products containing ephedrine or pseudoephedrine. During two different time periods, in 1995-1996 and in 1998-1999, the DEA placed restrictions on the importation of bulk ephedrine and tracked the sales of ephedrine and pseudoephedrine outside of “blis *664 ter packs.” According to the Counties, methamphetamine use and abuse declined dramatically during these time periods, but the Defendants allegedly fought to create loopholes in the regulations to continue reaping large profits in the sale of their products. In time, the Counties say, methamphetamine cooks learned how to exploit the loopholes, and methamphetamine use rose again.

The Counties claim that the Defendants knew of measures they could have voluntarily taken to reduce the availability of their products to methamphetamine cooks but consciously chose not to, fighting regulatory efforts in order to continue reaping large profits. The actions that the Defendants (who are manufacturers and wholesalers) allegedly should have voluntarily taken included directing the retailers to place the products behind the counter of retail stores; requiring the retailers to make retail purchasers sign for products when purchased from the retailer; educating the retailers and their employees about suspicious behavior by persons seeking to purchase the products for illegal use; requiring the retailers to lock the products in display cases; and requiring the retailers to limit the amount of product that could be purchased at retail by an individual during a specified period of time. These measures were eventually included in DEA regulations issued in 2005. The Counties also alleged that two of the Defendants, Warner Lambert and Pfizer, developed effective alternative cold medications that did not contain ephedrine or pseudoephed-rine and that could not be used to produce methamphetamine, but that neither of them brought the alternative products to market.

The Counties assert that the Defendants knew they were selling far more than the legitimate market for their products consumed as evidenced by the fact that the revenues of one of the Defendants, Perri-go, declined rapidly from $182 million to $30 million once regulations were passed in 2005 limiting access to the Defendants’ products. The Counties also allege that the DEA sent letters to some of the Defendants warning them that their products were being used to make methamphetamine and that an executive from Pfizer admitted that the pharmaceutical industry was responsible for a portion of the methamphetamine problem in the United States. The Counties do not allege, however, that any of the Defendants violated any federal or state regulation governing the manufacture, distribution, packaging, or sale of their products. Nor do the Counties dispute that the sale of products containing ephedrine and pseudoephedrine is heavily regulated by both state and federal agencies.

The Counties sought damages under four different causes of action: common law unjust enrichment; the Arkansas Deceptive and Unconscionable Trade Practices Act (ADTPA), see Ark Code Ann. § 4-88-107; common law nuisance; and the Arkansas crime victims civil liability statute, see Ark.Code Ann. § 16-118-107. The District Court granted the Defendants’ motion for judgment on the pleadings, 4 and the Counties appeal.

*665 II.

The Counties filed their case in Arkansas state court, and the Defendants removed it to federal court based on diversity of citizenship. 28 U.S.C. § 1332. We therefore apply federal procedural rules, see Scenic Holding, LLC v. New Bd. of Trustees of Tabernacle Missionary Baptist Church, Inc., 506 F.3d 656, 665 (8th Cir.2007), but Arkansas substantive law, see Bores v. Domino’s Pizza, LLC, 530 F.3d 671, 674 (8th Cir.2008).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Newman v. Wilson
E.D. Missouri, 2025
Keesee v. Johnson
E.D. Arkansas, 2024
William Salier v. Walmart, Inc.
76 F.4th 796 (Eighth Circuit, 2023)
Porter v. Hendrix
E.D. Arkansas, 2023
Floreal-Wooten v. Helder
W.D. Arkansas, 2023
National Union v. Cargill
61 F.4th 615 (Eighth Circuit, 2023)
Lippe v. Stone Bank
W.D. Arkansas, 2022

Cite This Page — Counsel Stack

Bluebook (online)
552 F.3d 659, 2009 U.S. App. LEXIS 19, 2009 WL 17992, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ashley-county-ark-v-pfizer-inc-ca8-2009.